Ozark Health Ventures LLC dba Cancer Research for the Ozarks (CRO)

1 Ozark Health Ventures，LLC d/b/a The Ozarks癌症研究(CRO)正在提交 2这项赠款申请是因为它希望继续参与合作努力 NCI社区肿瘤学研究计划(NCORP)的3个项目，以关注更广泛的 4癌症预防和治疗、癌症护理服务、成像研究和 5.癌症差异。 6奥扎克癌症研究与NCI有着悠久的互惠互利的历史 7在超过31年的时间里为中部农村社区提供临床试验机会 8美国。自成立以来，CRO已经从密苏里州西南部发展到 9将其网络扩大到15个组成部分，包括5个州的42个县 10个，以农村人口为主，超过430万人。CRO将成为 11 NCI赞助和NTCN网络试验的主要通道，适用于其中绝大多数 12例患者。CRO集水区的人口一般是高加索人，略有 13人比全国平均水平更老、更穷。CRO一直是 14参加癌症预防和治疗、癌症护理服务、 15项成像研究，以及癌症差异。CRO也有许多注册到 16个癌症护理服务和组织采购协议。CRO定期与NCI会面 17个注册标准和开放的CCDR协议数量。CRO有一个 18计划进一步扩大组件和调查人员，以确保更高的 19人报名。CRO参与了以下研究基础：联盟：成员自 2012年6月20日；NRG：自2014年合并以来的成员和之前的遗留集团； 21 SWOG：自1987年成立以来的成员；维克森林：自成立以来的成员 22在2014年，并参与了与以前的癌症中心的方案；ECOG-ACRIN： 自2014年以来有23个成员，以及之前的遗产团体。此外，CRO一直在 自2011年6月以来，24人参与了圣路易斯慈悲医院的儿童肿瘤学小组。这个 CRO应用程序的25个主要集体优势将是巨大的支持和 26两个主要组成部分的承诺、组成地点的广泛网络、 27 CRO领导层和项目的质量、正直和经验，以及许多 它支持的28名调查人员和合作者。 29

1 Ozark Health Ventures, LLC d/b/a Cancer Research for the Ozarks (CRO) is submitting 2 this grant application as it desires to continue to be involved with the cooperative efforts 3 of the NCI Community Oncology Research Program (NCORP) to focus on the broader 4 needs of cancer prevention and treatment, cancer care delivery, imaging studies and 5 cancer disparities. 6 Cancer Research for the Ozarks has a long and mutually beneficial history with the NCI 7 for over 31 years of offering clinical trial access to rural communities within the central 8 United States. Since its inception, CRO has grown from southwest Missouri, to 9 increasing its network to 15 component sites that incorporate 42 counties in five states 10 with a predominately rural population of more than 4,300,000. CRO would be the 11 primary access for NCI-sponsored and NTCN network trials for the vast majority of these 12 patients. The population in CRO’s catchment area is generally Caucasian, and slightly 13 older and poorer than national averages. CRO has been a significant contributor to 14 enrollments in protocols involving cancer prevention and treatment, cancer care delivery, 15 imaging studies, and cancer disparities. CRO has also had numerous registrations to 16 cancer care delivery and tissue procurement protocols. CRO routinely meets the NCI 17 criteria for enrollments and for the number of CCDR protocols it has open. CRO has a 18 plan for further expansion of components and investigators to secure even higher 19 enrollments. CRO participates with the following research bases: Alliance: member since 20 June, 2012; NRG: member since their merger in 2014 and the preceding legacy groups; 21 SWOG: member since its inception in 1987; Wake Forest: member since their inception 22 in 2014 and participated in protocols with the preceding Cancer Center; ECOG-ACRIN: 23 member since 2014 and the preceding legacy groups. In addition, CRO has been 24 involved in the Children’s Oncology Group at Mercy St. Louis since June 2011. The 25 major collective strengths of the CRO application would be the tremendous support and 26 commitment of the two primary components, the broad network of component sites, the 27 quality, integrity and experience of CRO’s leadership and the program, and the many 28 investigators and collaborators that it supports. 29